Nucleoside analogues are extensively applied as antiviral, antimicrobial or anticancer agents as they act as reverse transcriptase inhibitors or interfere with DNA or RNA synthesis. Due to the complexity and drawbacks of chemical synthesis routes, the biotechnologic and pharmaceutical industry are constantly searching for enzymatic or chemo-enzymatic synthesis routes. 

With the help of biocatalysts BioNukleo - a spin-off of the Technische Universität Berlin - develops new (chemo-) enzymatic synthesis routes for nucleic acid derivatives. Due to our strong competence in the expression of challenging proteins, we have set up enzyme libraries with wide substrate promiscuity. They allow for the production of a broad range of nucleoside and nucleotide analogs.

We strive to make nucleoside analog production less complicated, less polluting and less costly!